An expert panel of the European Medicines Agency (EMA) has endorsed expanding the marketing authorization for Arexvy, a ...

Arexvy is GSK’s adjuvanted recombinant vaccine designed to prevent lower respiratory tract disease (LRTD) caused by RSV. Initially approved for adults aged 60 and older, as well as those aged 50-59 ...

EMA committee recommends approval of GSK’s RSV vaccine, Arexvy for all adults 18 years and older: London, UK Saturday, December 13, 2025, 13:00 Hrs [IST] GSK plc announced that ...

The recommendation by the CHMP should now result in approval of Arexvy in the broader age range in February next year, and ...

GSK GSK announced that the FDA has approved the expanded use of its respiratory syncytial virus (RSV) vaccine, Arexvy for adults aged 50-59 who are at increased risk of RSV disease. Arexvy is ...

Investing.com -- GSK plc (LSE:GSK) announced Friday that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the indication of its RSV ...

GSK said on Friday a panel of the European Medicines Agency had backed the use of its respiratory syncytial virus (RSV) ...

After a 60-year scientific quest, the world has its first vaccine to protect against respiratory syncytial virus, or RSV -- and more are on the way. On Wednesday, the US Food and Drug Administration ...

Noninferior immune responses were observed in adults aged 50 through 59 when compared with adults aged 60 and older. The Food and Drug Administration (FDA) has approved Arexvy (respiratory syncytial ...

GSK (NYSE:GSK) announced Tuesday that Arexvy, a Phase 3 trial for its FDA-approved vaccine against Respiratory Syncytial Virus (RSV), generated protection against the virus over three full seasons in ...

GSK plc GSK has announced the approval of the European Commission (EC) for the expanded use of its respiratory syncytial virus (RSV) vaccine, Arexvy, in adults aged 50-59 years. The vaccine has been ...